What are ADC's

Our services

ADC Review
is made possible by:

NCT01028755 (Clinical Trial/ BAY79-4620)

Study Title
To Determine Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors (NCT01028755)

Trial Description
This is the first time this drug will be tested in humans in order to determine the safety of the drug, the ability to tolerate the drug, to measure how the drug is used in the body and as a result of these tests to determine a maximum dose to be given. Specifically, the following aspects will be investigated:

  • Side effects of BAY79-4620 given as infusion every three weeks
  • Evaluation of highest and safest dose of BAY79-4620
  • Distribution and concentration of BAY79-4620 in the blood at specific times after administration
  • Effect of BAY79-4620 on tumor growth
  • Assessment of “biomarkers” (eg, analysis of specific proteins in blood samples, or analysis of tumor tissue sampled at the time of cancer diagnosis) for
  • Changes during the treatment or prediction of safety or benefits of the treatment with BAY79-4620.

This trial is sponsored by Bayer. [1]

Study Data

  • Condition: Neoplasms
  • Interventions:
    • Drugs used in this trial
      • BAY79-4620
  • Phase: I
  • Enrollment: 12
  • Start: November 2009
  • Completion: April 2013
  • Last verified: January 2015

Study Schematic

Screen Shot 2016-07-06 at 4.30.59 PM

Click here to Return to Drug map

Last Editorial review: July 7, 2016
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...

Skip to toolbar